You are here: Industry Insights > HIV drug

News List

WHO halts hydroxychloroquine, HIV drugs in COVID trials after failure to reduce death expresspharma
July 07, 2020
The setback came as the WHO also reported more than 200,000 new cases globally of the disease for the first time in a single day.
Israel approves import of generic of AbbVie’s HIV drug for Covid-19 pharmaceutical-technology
March 23, 2020
Israel health ministry has approved the licensing of a generic version of AbbVie’s HIV drug Kaletra to treat Covid-19, as the cases in the country exceed 500.
AbbVie’s HIV drug combo shows no benefit in Covid-19 trial pharmaceutical-technology
March 20, 2020
A clinical trial in Covid-19 patients in China has yielded no therapeutic benefits with AbbVie’s HIV drug combination of lopinavir and ritonavir, marketed as Kaletra.
AbbVie to test HIV drug for Covid-19 treatment pharmaceutical-technology
March 12, 2020
AbbVie has announced plans to evaluate HIV medicine Kaletra / Aluvia (lopinavir / ritonavir) as Covid-19 treatment.
DelSiTech partners with Innovare to create long-acting HIV drug pharmaceutical-technology
December 19, 2018
Finnish drug delivery company DelSiTech has signed a licensing agreement with Mexico-based pharmaceutical group Innovare to develop a long-acting human immunodeficiency virus (HIV) therapy......
Aurobindo Pharma gets nod from South African health authority for HIV drug financialexpress
September 19, 2018
Aurobindo Pharma has received approval from the South African health authority to market its Dolutegravir
Janssen wins FDA nod for Symtuza but the once-daily HIV drug must now find its place in the market fiercepharma
July 23, 2018
Johnson & Johnson has won FDA approval for a new once-a-day HIV drug, adding to its growing portfolio of treatment options for the condition.
GlaxoSmithKline's next-generation HIV battle against Gilead is already taking a toll on growth fiercepharma
April 28, 2018
GlaxoSmithKline execs touted their HIV growth drive this week, pointing to next-generation medications Triumeq and Tivicay as the fuel.But both drugs actually fell short of analyst forecasts...